948 Results

People

  1. Kris
    Kris
  2. Kelsen
    Kelsen
  3. Motzer
    Motzer
  4. O'Reilly
    O'Reilly
  5. Saltz
    Saltz
  6. Tyson
    Tyson
  7. Gralla
    Gralla
  8. Hudis
    Hudis
  9. Scher
    Scher
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)
  7. Center for Hematologic Malignancies (109)
  8. Genitourinary Oncology Service (106)
  9. Nursing (101)
  10. Surgery (97)
  1. "vomiting"
Formats
  1. Journal Article (896)
  2. Review (27)
  3. Conference Paper (8)
  4. Editorial (6)
  5. Research Letter (4)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Book Section (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)

More Groups

People
  1. Mark Kris (70)
  2. David Kelsen (40)
  3. Robert Motzer (39)
  4. Eileen O'Reilly (30)
  5. Leonard Saltz (30)
  6. Leslie Tyson (28)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (44)
  4. 2022 (32)
  5. 2021 (15)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Cancer (47)
  3. Clinical Cancer Research (44)
  4. Lancet Oncology (38)
  5. Gynecologic Oncology (31)
  6. Cancer Treatment Reports (26)

More Publications

Publishers
  1. Elsevier Inc. (145)
  2. American Society of Clinical Oncology (92)
  3. Elsevier Science, Inc. (74)
  4. Springer (72)
  5. Oxford University Press (64)
  6. Wiley Blackwell (63)

More Publishers

Results (948)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Journal Article

    Dang, N. H.; Ogura, M.; Castaigne, S.; Fayad, L. E.; Jerkeman, M.; Radford, J.; Pezzutto, A.; Bondarenko, I.; Stewart, D. A.; Shnaidman, M.; more...
    British Journal of Haematology (2018)

    Fulltext@MSK | Save
  • PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
    Journal Article

    Migden, M. R.; Rischin, D.; Schmults, C. D.; Guminski, A.; Hauschild, A.; Lewis, K. D.; Chung, C. H.; Hernandez-Aya, L.; Lim, A. M.; Chang, A. L. S.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies
    Journal Article

    Mato, A. R.; Samp, J. C.; Gauthier, G.; Terasawa, E.; Brander, D. M.
    Cancer Biology and Therapy (2018)

    Fulltext@MSK | Save
  • Phase I study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment-naïve and previously treated basal cell carcinoma
    Journal Article

    Bendell, J.; Andre, V.; Ho, A.; Kudchadkar, R.; Migden, M.; Infante, J.; Tiu, R. V.; Pitou, C.; Tucker, T.; Brail, L.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential
    Journal Article

    Pak, L. M.; Kemeny, N. E.; Capanu, M.; Chou, J. F.; Boucher, T.; Cercek, A.; Balachandran, V. P.; Kingham, T. P.; Allen, P. J.; DeMatteo, R. P.; more...
    Journal of Surgical Oncology (2018)

    Fulltext@MSK | Save
  • 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): An international, randomised, phase 3, non-inferiority trial
    Journal Article

    Iveson, T. J.; Kerr, R. S.; Saunders, M. P.; Cassidy, J.; Hollander, N. H.; Tabernero, J.; Haydon, A.; Glimelius, B.; Harkin, A.; Allan, K.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children
    Journal Article

    Drilon, A.; Laetsch, T. W.; Kummar, S.; DuBois, S. G.; Lassen, U. N.; Demetri, G. D.; Nathenson, M.; Doebele, R. C.; Farago, A. F.; Pappo, A. S.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save
  • Cytokine release syndrome after radiation therapy: Case report and review of the literature
    Journal Article

    Barker, C. A.; Kim, S. K.; Budhu, S.; Matsoukas, K.; Daniyan, A. F.; D'Angelo, S. P.
    Journal for ImmunoTherapy of Cancer (2018)

    Fulltext@MSK | Save
  • Updates on primary central nervous system lymphoma
    Journal Article

    Schaff, L. R.; Grommes, C.
    Current Oncology Reports (2018)

    Fulltext@MSK | Save
  • Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies
    Journal Article

    Flinn, I. W.; O’Brien, S.; Kahl, B.; Patel, M.; Oki, Y.; Foss, F. F.; Porcu, P.; Jones, J.; Burger, J. A.; Jain, N.; more...
    Blood (2018)

    Fulltext@MSK | Save